Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Liver function test increased? 69 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 69 reports of Liver function test increased have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.1% of all adverse event reports for NATALIZUMAB.

69
Reports of Liver function test increased with NATALIZUMAB
0.1%
of all NATALIZUMAB reports
0
Deaths
19
Hospitalizations

How Dangerous Is Liver function test increased From NATALIZUMAB?

Of the 69 reports, 19 (27.5%) required hospitalization, and 1 (1.4%) were considered life-threatening.

Is Liver function test increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 69 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Liver function test increased?

METHOTREXATE (3,839) ADALIMUMAB (2,070) ETANERCEPT (1,829) LEFLUNOMIDE (1,521) ABATACEPT (1,415) TOCILIZUMAB (1,406) RITUXIMAB (1,325) SULFASALAZINE (1,263) HYDROXYCHLOROQUINE (1,259) TOFACITINIB (1,221)

Which NATALIZUMAB Alternatives Have Lower Liver function test increased Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Liver function test increased Reports All Drugs Causing Liver function test increased NATALIZUMAB Demographics